Clinical Trial: A Hase II/III Clinical Study to Evaluate HLX22 in Combination With HLX87 as First-Line Treatment in Patients With HER2-Positive Recurrent or Metastatic Breast Cancer

U.S., Dec. 20 -- ClinicalTrials.gov registry received information related to the study (NCT07294508) titled 'A Hase II/III Clinical Study to Evaluate HLX22 in Combination With HLX87 as First-Line Treatment in Patients With HER2-Positive Recurrent or Metastatic Breast Cancer' on Dec. 08.

Brief Summary: The study is being conducted to evaluate the clinical efficacy of HLX22 in combination with HLX87 as first-line treatment in patients with HER2-positive recurrent or metastatic breast cancer

Study Start Date: Jan. 25, 2026

Study Type: INTERVENTIONAL

Condition: HER2 + Breast Cancer

Intervention: DRUG: HLX87 + HLX22

HLX87 is a novel HER2-targeted ADC with a similar mechanism of action to trastuzumab deruxtecan. HLX22 is a novel monoclona...